2017
DOI: 10.1111/cas.13157
|View full text |Cite
|
Sign up to set email alerts
|

Vasohibin‐2 is required for epithelial–mesenchymal transition of ovarian cancer cells by modulating transforming growth factor‐β signaling

Abstract: Vasohibin‐2 (VASH2) is a homolog of VASH1, an endothelium‐derived angiogenesis inhibitor. Vasohibin‐2 is mainly expressed in cancer cells, and has been implicated in the progression of cancer by inducing angiogenesis and tumor growth. Although VASH2 has been recently reported to be involved in epithelial–mesenchymal transition (EMT), its precise roles are obscure. The aim of the present study was to clarify the role of VASH2 in the EMT of cancer cells in relation to transforming growth factor‐β (TGF‐β) signali… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

2
33
0

Year Published

2017
2017
2022
2022

Publication Types

Select...
7

Relationship

3
4

Authors

Journals

citations
Cited by 29 publications
(35 citation statements)
references
References 32 publications
2
33
0
Order By: Relevance
“…Our previous study showed that VASH2 modulates the metastatic potential of tumor cells through EMT by regulation of transforming growth factor beta (TGF‐β) signaling in ovarian cancer cells . We confirmed EMT markers in KPC cell lines and PDAC in KPC mice.…”
Section: Resultssupporting
confidence: 65%
See 2 more Smart Citations
“…Our previous study showed that VASH2 modulates the metastatic potential of tumor cells through EMT by regulation of transforming growth factor beta (TGF‐β) signaling in ovarian cancer cells . We confirmed EMT markers in KPC cell lines and PDAC in KPC mice.…”
Section: Resultssupporting
confidence: 65%
“…Whereas VASH1 is expressed in endothelial cells, VASH2, which is more similar to the ancestral VASH, is not expressed in normal tissues except in the testis after birth . However, VASH2 is overexpressed in various cancer cells, and promotes tumor angiogenesis, accumulation of CAF and EMT of cancer cells . VASH2 knockdown or blockade in cancer cells including human ovarian cancer and hepatocellular carcinoma showed significant anticancer effects, and VASH2 has consequently been identified as a potential molecular target for anticancer therapy.…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…Our results also demonstrated that VASH2 promotes tumor angiogenesis in hepatocellular carcinoma (HCC) cells . Subsequently, VASH2 was discovered as a promoter of EMT in human malignancies . VASH2 is localized in both cytosol and nucleus and is abnormally expressed in various types of cancer cells.…”
Section: Introductionsupporting
confidence: 57%
“…Transforming growth factor‐β (TGF‐β) signal is one of the most important pathways for CAF activation as well as tumor metastasis. VASH2 has been recently reported to be involved in epithelial–mesenchymal transition and the chemoprevention ability of cancer cells . We earlier found that VASH2 might accelerate TGF‐β‐induced epithelial–mesenchymal transition and invasiveness of ovarian cancer cells by modulating TGF‐β type I receptor expression, suggesting functional links between TGF‐β signal and VASH2 action in tumor progression …”
Section: Discussionmentioning
confidence: 93%